Dr. Smalberg is a radiology expert on quantitative imaging in oncology clinical trials, and is the CEO and founder of Radmetrix, a company that provides physician specialists for blinded independent central reviews for imaging in clinical trials using RECIST 1.1, iRECIST, Cheson, Lugano, Hallek and other imaging criteria. He is a central radiology reviewer for multiple national and international Phase 2 and Phase 3 clinical trials. Dr. Smalberg received his Medical Degree at the UCLA School of Medicine and completed his Residency in Radiology at North Shore University Hospital in Manhasset, NY. He also completed a fellowship in Abdominal Imaging at the New York University School of Medicine.